ArticleCancer cell2019
Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.
Open access · hybridAbstract read
In one paragraph
Article in Cancer cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 288 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
288citing papers in PubMed, 2 pooled it
19.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
288 citing papers in PubMed, 2 syntheses or guidelines pooled it, 437 citations in OpenAlex.
- The Prognostic Value of Tumor-Associated Neutrophils in Colorectal Cancer: A Systematic Review and Meta-Analysis.Cancer medicine · 2025Pooled it
- A state-of-the-art systematic review of cancer in hidradenitis suppurativa.Annals of medicine · 2024Pooled it
- Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.Nature communications · 2024Trial
- Modeling human tumor evolution in mice.STAR protocols · 2026Review
- Article
- A predictive nomogram model for overall survival in obstructive colorectal cancer based on clinical and laboratory indicators.Journal of gastrointestinal oncology · 2026Article
- Integrated bioinformatics analyses for GSDMB in carcinogenesis and progression of bladder cancer.Translational andrology and urology · 2026Article
- Article
- Mitochondrial metabolism determines chemotherapy sensitivity in colorectal cancer.Nature metabolism · 2026Article
- Inhibition of Colorectal Cancer Cell Progression by Picroside II Through Modulation of the Notch1 Signaling Pathway.Journal of biochemical and molecular toxicology · 2026Article
- NAT10 promotes colon cancer progression by enhancing predicted N4-acetylcytidine modification of Notch2 mRNA.Discover oncology · 2026Article
- NICD3 mediates pro-angiogenic effects through SMAD3/TGFBI axis in colorectal cancer.Cell death & disease · 2026Article
- Ras-MAPK inhibition induces AXIN1 loss in colorectal cancer by mTOR associated suppression of protein synthesis.Cell communication and signaling : CCS · 2026Article
- Viral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state.Communications biology · 2026Article
- Harnessing myeloid cell plasticity for cancer therapy.Nature cancer · 2026Review
- Pancancer Fine-Mapping of Mutational Intolerance Identifies CHEK1 as an Immunosuppressive Driver in Lung Adenocarcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Decoding notch signaling pathway: an updated insight into its role in colorectal cancer progression and therapy.Cancer cell international · 2026Review
- ADAM9 in tumor biology: molecular functions, clinical implications, and therapeutic targeting.Cellular & molecular biology letters · 2026Review
- MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance.Nature · 2026Article
- Spatiotemporal dynamics of tumor-associated neutrophils: bridging the gap between cancer progression and immunotherapy.Molecular cancer · 2026Review
228 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors at 10 institutions in 4 countries.
Rene JackstadtCancer Research UK Beatson Institute, Glasgow, UK.
Sander R van HooffLaboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
Joshua D LeachCancer Research UK Beatson Institute, Glasgow, UK; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow, UK.
Xabier Cortes-LavaudCancer Research UK Beatson Institute, Glasgow, UK.
Jeroen O LohuisCancer Research UK Beatson Institute, Glasgow, UK.
Rachel A RidgwayCancer Research UK Beatson Institute, Glasgow, UK.
Valérie M WoutersLaboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
Jatin RoperDepartment of Medicine, Division of Gastroenterology, Duke University, Durham, NC, USA.
Timothy J KendallDivision of Pathology/Centre for Inflammation Research, University of Edinburgh, UK.
Campbell S RoxburghAcademic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow, UK.
Paul G HorganAcademic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow, UK.
Colin NixonCancer Research UK Beatson Institute, Glasgow, UK.
Craig NourseCancer Research UK Beatson Institute, Glasgow, UK.
Matthias GunzerInstitute for Experimental Immunology and Imaging, University Hospital, University Duisburg-Essen, Essen, Germany.
William ClarkCancer Research UK Beatson Institute, Glasgow, UK.
Ann HedleyCancer Research UK Beatson Institute, Glasgow, UK.
Omer H YilmazDivision of Gastroenterology, Tufts Medical Center, Boston, MA, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Mamunur RashidWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Peter BaileyInstitute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow, UK.
Andrew V BiankinInstitute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow, UK.
Andrew D CampbellCancer Research UK Beatson Institute, Glasgow, UK.
David J AdamsWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Simon T BarryBioscience, Oncology R&D, AstraZeneca, Cambridge, UK.
Colin W SteeleCancer Research UK Beatson Institute, Glasgow, UK; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow, UK.
Jan Paul MedemaLaboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
Owen J SansomCancer Research UK Beatson Institute, Glasgow, UK; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow, UK. Electronic address: o.sansom@beatson.gla.ac.uk.
Cancer Research UK Scotland Institute · GBUniversity of Glasgow · GBAcademic Medical Center · NLWellcome Sanger Institute · GBAstraZeneca (United Kingdom) · GBCentre for Inflammation Research · GBDuke University · USOncode Institute · NLTufts Medical Center · USUniversity of Duisburg-Essen · DE
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8MVIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9MUnderstanding and Improving Platinum Anticancer DrugsR01CA034992 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILMAZ, OMER · 1985 to 2018
$6.8MImpact of fasting on intestinal stem cells and cancerR01CA245314 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Omer Yilmaz · 2020 to 2026
$2.3MDietary control of stem cells in physiology and cancerR01CA211184 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILMAZ, OMER · 2017 to 2021
$2.0MCancer Research UK 14356Cancer Research UK 21139Cancer Research UK 21717Cancer Research UK 23390Cancer Research UK 26018Cancer Research UK A12481Cancer Research UK A21139Cancer Research UK A23390Cancer Research UK A26825Cancer Research UK A28233Cancer Research UK C596/A17169Chief Scientist Office PCL/17/03Medical Research Council MR/N021800/1NCI NIH HHS P30 CA014051NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA034992NCI NIH HHS R01 CA211184NCI NIH HHS R01 CA245314
Abstract
The metastatic process of colorectal cancer (CRC) is not fully understood and effective therapies are lacking. We show that activation of NOTCH1 signaling in the murine intestinal epithelium leads to highly penetrant metastasis (100% metastasis; with >80% liver metastases) in Kras
Indexed as
Gene Expression Regulation, NeoplasticAnimalsColorectal NeoplasmsDatasets as TopicDisease Models, AnimalGene Expression ProfilingHumansIntestinal MucosaLiver NeoplasmsMaleMiceMutationNeutrophil ActivationNeutrophilsPrognosisProto-Oncogene Proteins p21(ras)Hras protein, mouseKRAS protein, humanNOTCH1 protein, humanNotch1 protein, mouseProto-Oncogene Proteins p21(ras)Receptor, Notch1Transforming Growth Factor betacolorectal cancer (CRC)consensus molecular subtype (CMS)CRC intrinsic subtypes (CRIS)metastasismolecular subtypingneutrophilsNOTCH1serrated CRCTGF-βtumor microenviroment (TME)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.